Dr. J and the Team have been keeping their cards close to

New Post Public Reply Private Reply Replies (4) Message Board
Katangolo
1,420
Dr. J and the Team have been keeping their cards close to the vest. This started before he came on board when we were handcuffed with the FDA hold. We had proactiv videos, YouTube interviews, etc; it all looked like a circus roadshow.

The powers that be didn’t like this for obvious reasons and the pendulum swung back viciously, giving us almost no communication during the Hold. CA Comes in and tells us the pendulum is swinging back and the team tells us we will be pleased with their new approach to communication with shareholders. So we then get quarterly calls and press releases.

Jay comes in with his quarterly letter to shareholders. Not much in terms of conference calls, and Q&A session sessions that we were used to for years. Basically we are told you can submit questions, but nothing’s really ever answered, and there are no direct communications with shareholders outside of the shareholder letters and press releases.

This is frustrating to many out there, but I’m OK with it because I think they have an endgame in mind. Our new PR firm seems to me to be brilliantly, rolling things out in a cadence that leads to the endgame and those with diamond hands, a steel gut and patience can manage this without the fret that other shareholders are experiencing right now.

The approach I see the company taking is - give us a few hints at the direction they are going and they don’t tell us when they begin the studies or the endeavors that they are hinting at but instead let the results happen first, and then inform us. They did this with glioblastoma, they did this with the mash trials, they did this with SMC labs., and they’re doing this with the work that Max, Richard, and Melissa are doing.

Do we think they are not working? Absolutely not. We’re getting breadcrumbs about what they are doing and we are, like I’ve said for a while, putting pieces of a puzzle together. Collecting the breadcrumbs. The real problem, which is actually a gift, are the NDA’s, which are in place. We’ve been told since the times of Scott Kelly that multiple NDA’s are in place. And subsequent levels of leadership have also told us NDA’s are in place.

I believe we are in a silent period now because of those NDA’s. If the suppositions above that I am positing are true, the company can’t say anything to begin with and their m.o. has them with a results first, then inform (shareholders) later, approach.

So back to the question about what is actually going on right now. This has me thinking that the trials with Trodelvy and Keytruda are underway if not finished. Glioblastoma as well. The same possibilities strongly lead me to believe this is the case with fibromyalgia, Alzheimer’s, pulmonary fibrosis possibly HIV and inflammation although my gut says this has been shelved, CRC & mTNBC. Jonah is working hard on an HIV cure and we are getting strong clues that BMGF is involved in probably making moves behind the scenes.

So yes, this is frustrating from a shareholder perspective (or is it?) because we want to know what’s going on and we would like to share price to go up. Come back to the concept of the NDA‘s, which hamstrings the company from telling us anything but allows them to be sitting at a table negotiating with all of the big Pharma, who are salivating over the very real possibility that, through a negotiation, they can get access to controlling and developing this molecule for the indications they are interested in. Hopefully one company wins it all and doesn’t piecemeal the indications but we don’t lose at all if for example, BMFG gets HIV and someone else gets fibrosis, etc.

These negotiations take time. We have a lot of evidence that negotiations are going on right now. Silence is certainly a big clue. So Jay drops a few press releases to keep us happy and let us know what they have been working on and shareholder letters give us clues as to what they actually are working on.

It’s an honor for me to be a part of this group of people; these Internet sleuths, made up of lawyers, researchers, lay people who are investors, doctors, engineers, and beyond. Collectively, we put our pieces out there for each other to digest and synthesize a story that’s becoming more beautiful each day. It helps filling the gaps of the silence we sit with.

But that silence is leading us to what I believe will be the promised land. Patience leads to Patients.

All IMHO and certainly not financial advice. Just hope.

GLTAL

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Protalix to Reveal Q3 2026 Results Amid Rare Disease Push

Updated Category News Views 49

Looking Ahead to Protalix's Q3 Revelation Nobody's pretending it's a cakewalk to stay ahead in the biopharma sector, especially when you're tangoing with the unpredictable world of rare disease therapeutics. But here we are, with Protalix BioTherapeutics scheduling their third-quarter financial results announcement for November 10, 2026. If you've been tracking them—or...

Continue Reading
Tokenized Securities: Transfer Online's Next Frontier

Updated Category News Views 0

Transfer Online Teams Up with OnchainTA Hold onto your investment hats, folks—Transfer Online is linking arms with OnchainTA to step right into the future playground of tokenized securities. Now, what's that mean? Well, it's like jumping from sailing schooners to speedboats; we're entering a whole new era in capital markets. What's At Stake? The pair-up between these...

Continue Reading
Xi's Financial Vision: China's Path to Global Power

Updated Category News Views 122

China's Grand Financial Strategy Alright, strap in as President Xi Jinping is back on the scene painting a bold picture for China's financial future. The guy doesn't mess around when he says finance is a linchpin for the country's modernization. China's got the pedal to the metal, aiming to transform its national clout into a financial juggernaut. Key Pillars of Financial...

Continue Reading
Kirk Goehring: A Profile in Emerging Banking Leadership

Updated Category News Views 164

A Rising Star in the Banking World You don't see a lot of folks these days making waves in the banking sector quite like Kirk Goehring has. And it's a decent feat, earning a nod from the American Bankers Association (ABA) as one of their 2026 Emerging Leader Awards recipients. For those of you wondering if this is just another hollow accolade, think again. The ABA doesn't...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 110

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
Newcomers, Veterans Elevate NYSE's Tokenization Efforts

Updated Category News Views 89

Breaking New Ground at the NYSE When the bell rings at the NYSE these days, it's not just marking the start of another trading session. It's the sound of change clanging its way onto Wall Street. On November 3, 2026, the NYSE threw its hat deeper into the tokenization ring, a game-changer perhaps. They've roped in some big guns—Securitize, tZERO, Broadridge Financial...

Continue Reading
Autoliv Snaps Up MCF Safety Belts to Boost Growth

Updated Category News Views 82

Strategic Moves in Vehicle Safety Listen up! Autoliv is playing its cards right by snatching up Italy's MCF Safety Belts. Even for us with skin in the automotive game, it's clear why this matters. We're not talking just any acquisition, but one that steers Autoliv beyond conventional passenger cars. By grabbing MCF's niche expertise, Autoliv is showing it's ready to...

Continue Reading
PATEO Drives In-Car AI Forward with NVIDIA Power

Updated Category News Views 73

Revolutionizing In-Vehicle AI with Big Names Boy, driving ain't what it used to be, and PATEO's latest adventure has a lot to do about it. They've hooked up with some major players like NVIDIA and ByteDance to really shake up the in-car AI scene. We're not just talking bells and whistles, but a true reinvention trying to blend AI straight into our daily grind on the road....

Continue Reading
New Xavier Ochsner College of Medicine Opens Applications

Updated Category News Views 102

Paving New Paths in Medical Education Out of the vibrant hub of New Orleans comes a fresh twist in the world of medical education: the Xavier Ochsner College of Medicine is now taking applications for its 2027 debut class. The key here is a powerhouse collaboration between Xavier University of Louisiana and Ochsner Health. These are big names in their own right,...

Continue Reading
Edible Oils: Market Growth, Trends, and Investments

Updated Category News Views 90

Riding the Edible Oil Wave The edible oils market seems to be gearing up for a steady rise. Folks, the numbers are speaking loud and clear. We're looking at the market booming from USD 277.74 billion in 2026 to a hefty USD 351.08 billion in 2031. According to MarketsandMarkets™, a compound annual growth rate (CAGR) of 4.8% is on the cards. Now, if that doesn't get the...

Continue Reading

Top 5 Most Recently Viewed Articles

Comedy Show 'Office Joe' Highlights Veterans' Journeys

Updated Category News Views 250

New Comedy Series "Office Joe" Showcases Veterans' Experiences "Office Joe" is an exciting new television comedy series that shines a light on the challenges veterans often encounter as they transition back into civilian life. This innovative show is set to debut soon, featuring an all-star cast made up of military-affiliated entertainers and entrepreneurs who know...

Continue Reading
Exploring the Growth of the Global Glucose Syrup Market

Updated Category News Views 184

Understanding the Glucose Syrup Market Dynamics The glucose syrup market is primarily propelled by its increasing demand in the food and beverage sector. The versatile applications and advantages of glucose syrup within the pharmaceutical industry are also significant factors driving its growth and acceptance across diverse markets. This upward trajectory is expected to...

Continue Reading
Humorous Writing Opportunity Awaits at University of Dayton

Updated Category News Views 120

A Unique Opportunity for Aspiring Humor Writers Exciting news is making headlines for writers who love to tickle funny bones! The University of Dayton's renowned humor writing residency program, titled 'A Hotel Room of One's Own: The Erma Bombeck Humorist-in-Residence Program,' is now accepting applications. It's the perfect chance for humor writers to immerse themselves...

Continue Reading
Insider Selling Alert: Brian Poff Sells $904K Worth of ADUS Shares

Updated Category News Views 168

Understanding Recent Insider Trading at Addus HomeCare A significant insider sell transaction recently came to light, highlighting the financial dynamics at Addus HomeCare Corp. The executive vice president, Brian Poff, made headlines by selling 7,739 shares of company stock, amounting to a total value of $904,087. This transaction was reported through a Form 4 filing, a...

Continue Reading
Absci Corporation's Upcoming Financial Update: Key Insights

Updated Category News Views 62

Absci Corporation's Upcoming Financial Update: Key Insights Absci Corporation (Nasdaq: ABSI), a leading player in generative AI-driven drug creation technology, is set to announce its business updates alongside its financial and operating results for the third quarter. This eagerly awaited report is scheduled for early release, presenting an exciting moment for investors...

Continue Reading